Myrtelle Launches Commercial Manufacturing First-in-Class Gene Therapy
Myrtelle Launches Commercial-Stage Manufacturing of First-in-Class Gene Therapy for Canavan Disease.
This article is featured on another website.
Myrtelle to Present Breakthrough Insights at ASGCT 2025 New Orleans
The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.
Myrtelle to Present Breakthrough Insights at ASGCT 2025 New Orleans
The session — “FDA’s START Pilot Program in Action: Insights from Year One”—will spotlight Myrtelle’s experience in this bold regulatory initiative designed to fast-track therapies for rare and life-threatening diseases.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections.